DeCure's autonomous Respiratory AI scientist is researching a drug-repurposing hypothesis for bronchopulmonary dysplasia — screening already-approved drugs against its 12-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBronchopulmonary dysplasia maps to a 12-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedCaffeineAdenosine receptor antagonist
Structures already discussed alongside bronchopulmonary dysplasia in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Crystal structure of Aspergillus fumigatus chitinase B1 — Caffeine has a real, experimentally solved structure in complex with this target (PDB 2A3B, 1.9 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet cffdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2A3B · 1.9 Å · ligand Caffeine (CFF). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cardiovascular Diagnosis and Therapy · 2019 · 1 citations · open access
Systemic artery-pulmonary artery fistulae of adult bronchopulmonary dysplasia characterized with dynamic CT angiography and multiphase 3D-volumetric reconstruction: a case report
AbstractWe present a case of bronchopulmonary dysplasia in an adult survivor to demonstrate the utility of dynamic computed tomography angiography and multiphase 3D-volumetric reconstruction for complete characterization of the systemic artery-pulmonary artery fistulae which can occur with this pathological entity.
International journal of pediatrics · 2018 · 0 citations
Progress of caffeine in preventing bronchopulmonary dysplasia in preterm infants
AbstractCaffeine is a methylxanthine, clinically used to treat apnea in preterm infants.However, it has been found that the drug also has a role in reducing the incidence of bronchopulmonary dysplasia(BPD)in preterm infants in recent years.It may be related to improvement of lung function, improvement of extubation success rate and shortening of ventilator assisted ventilation time.Further study found that caffeine could play a protective role in the prevention and control of BPD by antagonistic adenosine receptors, inhibiting inflammatory mediators, inhibiting the transforming growth factors-β1, and inhibiting matrix metalloproteinases.
Key words:
Caffeine; Premature infants; Bronchopulmonary dysplasia
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
